EODData

FRA, 1T3: Syndax Pharmaceuticals Inc

14 Aug 2026
LAST:

16.41

CHANGE:
 0.66
OPEN:
16.41
HIGH:
16.41
ASK:
0.00
VOLUME:
0
CHG(%):
3.84
PREV:
17.07
LOW:
16.41
BID:
0.00
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
14 Aug 2616.4116.4116.4116.410
13 Aug 2617.0717.0717.0717.070
12 Aug 2617.4917.4917.4917.490
07 Aug 2617.0117.3717.0117.370
06 Aug 2617.1617.1617.1617.160
05 Aug 2615.4615.4615.4615.460
04 Aug 2616.6516.6516.6516.6530
03 Aug 2616.5116.5116.5116.510
31 Jul 2616.9116.9116.9116.910
30 Jul 2616.7116.7116.7116.710

PROFILE

Name:Syndax Pharmaceuticals Inc
About:Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:730 Third Avenue, New York, NY, United States, 10017
Website:https://syndax.com
ISIN:US87164F1057
LEI:529900OF94TRHKZVBS87

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:-6.47 
Forward P/E:-8.96 
PEG Ratio:0.13 
Price to Sales:8.74 
Price to Book:51.94 
Profit Margin:-1.12 
Operating Margin:-0.53 
Return on Assets:-0.25 
Return on Equity:-1.90 
Revenue:190.42M 
Shares:86.14M 
Market Cap:1.414B 

TECHNICAL INDICATORS

MA5:17.104.2%
MA10:16.772.2%
MA20:17.838.6%
MA50:17.627.3%
MA100:18.3812.0%
MA200:16.082.0%
STO9:46.91
STO14:31.30
RSI14:33.68 
WPR14:-68.70
MTM14:-2.09
ROC14:-0.11 
ATR:0.60 
Week High:17.496.6%
Week Low:16.410.0%
Month High:20.9927.9%
Month Low:15.462.0%
Year High:21.6632.0%
Year Low:11.2046.5%
Volatility:37.08